Pharmacovigilance: A worldwide master key for drug safety monitoring

Journal of Young Pharmacists

Volumn 2, Issue 3, 2010, Pages 315-320

  Jeetu, G ^a   Anusha, G ^b  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b IPS College of Pharmacy   (India)

Author keywords

Drug safety; erice declaration; pharmacovigilance

Indexed keywords

INFLUENZA VACCINE;

ALLERGIC REACTION; CLINICAL RESEARCH; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; FEVER; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFLUENZA A (H1N1); INJECTION SITE REACTION; INTERNET; MEDICAL INFORMATION; NAUSEA; PANDEMIC; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 77955870497     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.66802     Document Type: Review

References (29)

1. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Available from: http://www.whqlibdoc.who.int/hq/2004/WHO-EDM- 2004.8.pdf. [cited on 2009 Dec 15].
2. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008;64:743-52.
3. Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol 2007;39:124-8.
4. The Importance of pharmacovigilance Safety monitoring of medicinal products. WHO Lib Catalog. 2002. Available from: http://www.apps.who.int/ medicinedocs/en/d/Js4893e/. [last cited on 2009 Dec 25].
5. whqlibdoc.who.int [homepage on the Internet]. Geneva: World Health Organization. 1973. Handbook of resolutions and decisions of the World Health Assembly and Executive Board. Available from: http://whqlibdoc.who.int/wha-eb- handbooks/9241652063-Vol2.pdf. [Last cited on 2009 Dec 26].
6. Lared NL. Pharmacists′ role in reporting adverse drug reactions in an international perspective. 2003. Available from: http://www.lareb.nl/ documents/pds2004-1291.pdf. [last cited on 2010 Jan 28].
7. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003. Available from: http://www.apps.who.int/ medicinedocs/en/d/Jwhozip16e/8.html. [last cited on 2010 Jan 10]
8. Olsson S. The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf 1998;19:1-10.
9. Coulter DM. The New Zealand intensive medicines monitoring programme in proactive safety surveillance. Pharmacoepidemiol Drug Saf 2000;9:273-80.
10. Mackay FJ. Post-marketing studies: The work of the drug safety research unit. Drug Saf 1998;19:343-53.
11. Folb PI, ten Ham M. Drug monitoring in developing countries: A drug regulator′s perspective. Drug Inf J 1995;29:303-5.
12. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol 1998;45:427-31.
13. Moore N. The role of the clinical pharmacologist in the management of ADRs. Drug Saf 2001;24:1-7.
14. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of ADRs by nurses. Br J Clin Pharmacol 1995;40:173-5.
15. Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter: A 15-year review (1983 to 1997). Drug Inf J 1999;33:1117-24.
16. Cioms CH. Geneva. Benefit-risk balance for marketed drugs. Evaluating safety signals: Report of CIOMS working group IV. CIOMS, Geneva. 1998. Available from: http://www.cioms.ch/publications/g4-benefit-risk.pdf. [last cited on 2010 Jan 15].
17. Lazarou J, Pomeranz BH, Corey PN. Incidence of ADRs in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc 1998;279:1200-5.
18. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics 1999;15:445-58.
19. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-35.
20. Ball LK, Evans G, Bostrom A. Risky business: Challenges in vaccine risk communication. Pediatrics 1998;101:453-8.
21. Bapna JS, Tripathi CD, Tekur U. Drug utilization patterns in the third world. Pharmacoeconomics 1996;9:286-94.
22. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C, and human immunodeficiency virus through safe injections in the developing world: mode-based regional estimates. Bull World Health Organ 1999;78:801-7.
23. de Vries CS, Duggan CA, Tromp TF, de Jong-van den Berg LT. Changing prescribing in the light of tolerability concerns: How is this best achieved? Drug Saf 1999;21:153-60.
24. Sleath B, Svarstad B, Roter D. Physician motivation for non-scientific drug prescribing. Soc Sci Med 1997;44:541-8.
25. Vaccine safety. Vaccine Safety Advisory Committee. Wkly Epidemiol Rec 1999;74:337-40.
26. Pandemic pharmacovigilance weekly update Status. 2009. Available from: http://www.ema.europa.eu/pdfs/influenza/78468109en.pdf. [last cited on 2010 Jan 12].
27. Effective communications in Pharmacovigilance. The Erice Report. International Conference on Developing Effective Communications in Pharmacovigilance, Erice, Sicily. 1997. Available from: http://www.who-umc.org/ DynPage.aspx?id=22690. [last cited on 2010 Jan 20].
28. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001;285:437-43.
29. Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. BMJ 1992;304:1470-2.